Multifunctional Antibody Constructs With Site-Specific Payload Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating multifunctional antibodies, particularly bispecific and trispecific antibodies, face challenges such as low yield, high cost, and unpredictable results due to random chemical conjugation, and recombinant DNA technologies have limitations in controlling site-specificity and stoichiometry.
Innovation Solution
Development of multifunctional antibody constructs that attach two distinct payloads to an antibody without genetic engineering, using site-specific chemical conjugation methods to ensure precise attachment of functional moieties like cytotoxins, polypeptides, or oligonucleotides, thereby enhancing control over the antibody's structure and functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If random chemical conjugation is used to attach functional moieties to antibodies, then the process is simple and does not require genetic engineering, but the yield is low, cost is high, and results are unpredictable
Solution Approach 1:
The patent introduces site-specific chemical conjugation methods that attach functional moieties to specific locations on the antibody molecule (such as engineered cysteine residues or lysine residues at defined positions). This ensures uniform attachment sites and predictable stoichiometry, resolving the unpredictability of random conjugation while maintaining chemical synthesis simplicity.
Solution Approach 2:
The patent employs preliminary engineering of the antibody with specific reactive groups (such as introducing non-natural amino acids or engineered cysteines at predetermined positions) before conjugation. This preliminary action enables controlled and reproducible attachment of functional moieties, improving manufacturing precision without requiring complex genetic engineering of the entire antibody sequence.
2Manufacturing precision
If recombinant DNA technology is used to genetically fuse protein agents to antibodies, then site-specificity can be improved, but the complexity of the manufacturing process increases and costs rise
Solution Approach 1:
The patent uses chemical conjugation reagents as intermediaries to bridge the antibody and functional moieties. This chemical mediation approach achieves site-specific attachment without requiring complex genetic fusion procedures, thereby maintaining manufacturing precision while reducing process complexity and avoiding the need for cell culture and protein expression systems.
Solution Approach 2:
The patent replaces the mechanical/biological system of genetic fusion and protein expression with a chemical conjugation system. This substitution uses well-established chemical reactions (such as maleimide-thiol or click chemistry) to attach functional moieties, simplifying the manufacturing process while maintaining control over site-specificity and stoichiometry.
3Adaptability or versatility
If genetic engineering is used to modify antibody structure, then specific properties can be introduced, but the time required for development and production increases
Solution Approach 1:
The patent performs preliminary introduction of reactive groups into the antibody (such as enzymatic tagging or incorporation of non-natural amino acids) that enable subsequent rapid conjugation of diverse functional moieties. This preliminary action allows the same engineered antibody scaffold to be quickly adapted to different therapeutic agents, reducing development time while maintaining functional versatility.
Solution Approach 2:
The patent creates a universal antibody platform with engineered reactive sites that can accept multiple different types of functional moieties (cytotoxins, radionuclides, PEG chains, etc.). This universal platform approach allows rapid development of different therapeutic variants from a single antibody scaffold, significantly reducing overall development time while maintaining adaptability.
4Ease of manufacture
If chemical conjugation is used to attach multiple functional moieties, then the process avoids genetic engineering, but control over stoichiometry and homogeneity is poor
Solution Approach 1:
The patent introduces site-specific chemical conjugation methods that attach functional moieties to specific locations on the antibody molecule (such as engineered cysteine residues or lysine residues at defined positions). This ensures uniform attachment sites and predictable stoichiometry, resolving the unpredictability of random conjugation while maintaining chemical synthesis simplicity.
Solution Approach 2:
The patent employs controlled chemical reaction parameters (such as molar ratios, reaction time, temperature, and pH) to achieve precise control over the number and position of attached functional moieties. By optimizing these parameters, the method produces homogeneous antibody conjugates with defined drug-to-antibody ratios, improving compositional stability while maintaining ease of manufacture.
Data Source
AI summary
The present invention concerns multifunctional antibody construct containing at least one antibody Ab and two distinct payloads D1 and D2 of structure (1) or (2). Wherein L1, L2, L3, L4 and L5 are linkers; x1 and x2 are each individually an integer in the range of 1-8, wherein x1+x2=2-10; BM is a branching moiety; m and n are each independently 0 or 1; x3 is an integer in the range of 1-4; and D1 and D2 are two distinct payloads selected from the group consisting of polypeptides, small molecules, cytotoxins and oligonucleotides, wherein at least one of D1 and D2 is a polypeptide. The multifunctional antibody construct according to invention are suitable for use in medicine, such as for use in the treatment of cancer, a viral infection, a bacterial infection, a neurological disease, an autoimmune disease, an eye disease, hypercholesterolemia and amyloidosis.